Rick discusses the significant progress made in psychedelic research over the past 37 years, highlighting the potential FDA approval on the horizon. He emphasizes the challenges posed by the rise of for-profit psychedelic companies, which have complicated fundraising efforts. Despite these hurdles, the nonprofit's unique position as the sole owner of a for-profit pharmaceutical entity offers a promising path forward.
